AI interpretation based on checked source excerpts. Issuer assertions and evidence limitations remain explicit.
Policy quality-scores-2: six equally weighted categories. The overall score requires full coverage. Missing inputs are not zero. Qualitative grades are sourced interpretations, not probabilities. 5/6 · 18/10/2026
Moat25
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
structural advantage · 1/4 · Selected product protections offer limited shelter, but realized generic pressure and authorization of multiple competing generics outweigh the unsupported claim that scale creates a structural advantage.
durability · 1/4 · Protection is product-specific and finite; possible Amitiza entry and the failed European authorization challenge illustrate erosion. Clinical endpoints establish development progress rather than durable commercial protection.
customer dependency · 1/4 · Observed volume loss and increased buyer leverage indicate weak supplier indispensability. This assessment uses indirect operating evidence; the passages do not quantify switching costs or customer retention.
erosion resilience · 1/4 · Tender-related sales weakness and branded-product price and volume erosion persist. Stable adjusted quarterly margins provide a partial offset, while manufacturing disruption exposes another vulnerability.
Pricing power25
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
realized pricing · 0/4 · Actual branded-product price cuts in China and implemented government reductions directly establish adverse pricing outcomes. Continuing tender effects reinforce the weakness; market-wide extreme bid cuts are not treated as Viatris-specific reductions.
retention · 1/4 · Disclosed branded-product volume losses and tender-related sales pressure suggest fragile demand retention under competition. This is an indirect assessment, without a fabricated retention rate.
margin resilience · 2/4 · Second-quarter GAAP gross margin improved from 37% to 39%, primarily through mix, while adjusted margin remained approximately 57%. Manufacturing charges temper this resilience, and these outcomes do not establish pricing power.
contractual freedom · 1/4 · Viatris can submit tender bids, but underbidding, government price reductions and powerful consolidated buyers substantially constrain practical price-setting freedom.
Predictability75
Five consecutive annual periods. Equal weights: nondeclining revenue frequency; revenue-growth volatility (5–40pp); positive FCF frequency; FCF-margin volatility (3–20pp). Stability indicator, not a growth forecast.
- Nondeclining revenue years (%)
- 0.00
- Revenue growth volatility (pp)
- 2.19
- Positive FCF years (%)
- 100.00
- FCF margin volatility (pp)
- 0.99
Financial strength15
Equal-weight grades: debt/FCF (1–8x), net debt/earnings before interest and tax (0–5x), interest service (1–12x), current ratio (0.75–2x). Earnings use reported operating income, or reported pretax profit plus reported interest expense when operating income is unavailable. Interest service uses earnings/interest expense; if unavailable, it uses reported operating cash flow/cash interest paid, without relabeling cash paid as accrued expense. Nonpositive cash flow/earnings score 0 for their service component; reported zero interest with a positive numerator scores 100. Net cash scores 100 for net leverage. Missing disclosures remain unavailable. General nonfinancial-company rubric, not a credit rating; exceptional and nonoperating gains are not normalized out. IFRS finance-cost and cash-flow classifications retain their reported scope.
- debtFcfGrade
- 8.01
- netDebtEbitGrade
- 0.00
- interestCoverageGrade
- 0.00
- currentRatioGrade
- 50.39
- Debt / FCF (x)
- 7.44
- Interest coverage (x)
- -5.65
- Current ratio (x)
- 1.38
Capital allocation—
Missing required inputs: dilution. Three-year equal-weight indicators: pretax return on average invested capital (0–25%; equity + debt − cash, each year and its prior year), share-count growth (0–5%, lower better), share-based cost/revenue (2–20%, lower better), consolidated FCF/net income (0–1x). Return uses reported operating income or, if unavailable, EBIT calculated from reported pretax profit plus reported interest expense; exceptional/nonoperating gains are not normalized out. Share-based cost uses the reported cash-flow add-back or, if absent, separately reported recognized compensation expense; the latter never becomes an FCF adjustment. Nonpositive net income scores 0 for cash conversion; absent income/FCF stays unavailable. Nonpositive invested capital has no defined return and remains unavailable. Does not establish acquisition quality or buyback timing.
- 3-year pre-tax operating return (%)
- -2.30
- 3-year average SBC / revenue (%)
- 1.14
- cashConversionGrade
- 0.00
Management50
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
capital discipline · 2/4 · Completed capital returns demonstrate deployment discipline in a limited sense, while the $184.6 million Mapi-related charges show an investment setback. Missing cash-flow, financing and investment-return detail prevents a stronger assessment.
incentive alignment · 2/4 · Disclosed TSR linkage, ownership multiples and the adopted exclusion of unvested performance awards support alignment. Unvested RSUs still count, compliance wording is qualified, and realized pay-performance outcomes are absent.
execution · 2/4 · Positive Phase 3 endpoints and comparative gross-profit improvement demonstrate progress, balanced by realized manufacturing losses, supply disruption and the Mapi impairment. Commercial execution is assessed partly from indirect operating results rather than management's characterization.
governance · 2/4 · Independent committee composition, substantive independent-chair authority and an approved clawback policy establish concrete governance safeguards. Their effectiveness and sustained accountability outcomes are not demonstrated by the supplied passages.
Evidence
As we focus on developing or acquiring innovative, best-in-class, patent-protected assets, competition from manufacturers of generic or biosimilar drugs, including from generic versions of competitors’ branded products that lose their market exclusivity, has been and will continue to be a major challenge for our patent-protected and branded products.
Risk factors: competition affecting patent-protected and branded products · Filed 26/02/2026
In both Phase 3 studies, all primary and key secondary endpoints were met and MR-107A-02 demonstrated statistically significant and clinically meaningful results.
2025 accomplishments: meloxicam Phase 3 endpoints · Filed 26/02/2026
For example, generic entry for Amitiza® 24 μg may occur in Japan in December 2026 depending on the outcome of patent litigation.
MD&A: possible Amitiza generic entry in Japan · Filed 06/08/2026
In China, for example, we face strong competition from certain generic manufacturers, which has resulted and may in the future result in price cuts and volume loss on some of Viatris’ branded products without patent term and/or regulatory protection.
Risk factors: realized branded-product price cuts and volume loss in China · Filed 26/02/2026
Sales continue to be negatively affected by the impact of tender systems in certain countries.
MD&A: continuing negative tender impact on sales · Filed 06/08/2026
The European Commission or national regulatory agencies may grant marketing authorizations to any number of generics.
Risk factors: authorization of multiple generics in Europe · Filed 26/02/2026
Viatris Charter Amended and restated certificate of incorporation of Viatris Inc., as amended WHO World Health Organization YEN Term Loan Facility The ¥40 billion term loan agreement dated as of July 1, 2021, among Viatris, the guarantors from time to time party thereto, the lenders from time to time party thereto and Mizuho Bank, Ltd., as administrative agent 7 Table of Contents PART I ITEM 1.Business About Viatris Viatris is a global healthcare company whose breadth and scale we believe make it uniquely positioned to address healthcare needs globally.
Item 1 Business: management assertion concerning breadth and scale · Filed 26/02/2026
This consolidation has resulted in these groups gaining additional purchasing leverage and, consequently, increasing the product pricing pressures facing our business.
Risk factors: customer consolidation and increased purchasing leverage · Filed 26/02/2026
In addition, a significant amount of our sales are to a relatively small number of drug wholesalers and retail drug chains.
Risk factors: sales concentration among wholesalers and retail chains · Filed 26/02/2026
Under such tender systems, manufacturers submit bids that establish prices for generic pharmaceutical products.
MD&A: manufacturers establish tender prices through bids · Filed 06/08/2026
The tender system often results in companies underbidding one another by proposing lower pricing in order to win the tender.
MD&A: tender underbidding · Filed 06/08/2026
have undergone government-imposed price reductions, and further government-imposed price reductions are expected in the future.
MD&A: implemented government price reductions · Filed 06/08/2026
Gross profit for the three months ended June 30, 2026 was $1.46 billion and gross margins were 39%.
Quarterly results: second-quarter 2026 gross profit and margin · Filed 06/08/2026
For the three months ended June 30, 2025, gross profit was $1.33 billion and gross margins were 37%.
Quarterly results: second-quarter 2025 gross profit and margin · Filed 06/08/2026
The changes in gross profit and gross margins are primarily driven by product mix.
Quarterly results: product mix explanation for gross margin changes · Filed 06/08/2026
Adjusted gross margins were approximately 57% for the three months ended June 30, 2026, compared to approximately 57% for the three months ended June 30, 2025.
Quarterly results: comparative adjusted gross margins · Filed 06/08/2026
During the three and six months ended June 30, 2026, the Company recognized total charges of $14.9 million and $86.8 million, respectively, within Cost of Sales in the condensed consolidated statements of operations primarily related to the write off of inventory and fixed assets damaged in the fire and incremental manufacturing variances.
Manufacturing disruption: inventory, fixed-asset and manufacturing charges · Filed 06/08/2026
While production at the facility has resumed, the temporary manufacturing suspension due to the fire at the facility in February along with these intermittent disruptions are expected to impact product supply in the second half of the year.
Manufacturing disruption: resumed production and expected supply impact · Filed 06/08/2026
As a result of the uncertainty of regulatory and commercial timing and success of GA Depot and the financial condition of Mapi, the Company fully impaired its equity investment and prepaid assets related to advances for the initial supply of commercial product.
Mapi investment: full impairment following regulatory and commercial uncertainty · Filed 26/02/2026
Total charges of $184.6 million were recorded during the year ended December 31, 2024 as a component of Other Expense (Income), Net in the consolidated statements of operations.
Mapi investment: recorded 2024 charges · Filed 26/02/2026
During the three months ended June 30, 2026, the Company repurchased approximately 9.4 million shares of common stock at a cost of approximately $150.0 million under this program.
Share repurchases: completed second-quarter 2026 purchases · Filed 06/08/2026
We prioritized capital return with more than $1 billion returned to shareholders through dividends and share repurchases.
Shareholder letter: reported 2025 capital returns · Filed 02/04/2026
We aligned executive compensation with shareholder interests by linking pay to the Company’s stated strategic priorities, long-term performance, and share price appreciation, including through the use of a relative TSR modifier for PRSUs in our long-term incentive plan and robust share ownership requirements.
Compensation discussion: relative TSR modifier and ownership requirements · Filed 02/04/2026
During 2025, our Compensation Committee strengthened our required executive share ownership guidelines by no longer counting unvested PRSUs and corresponding dividend equivalent units toward ownership thresholds.
Compensation policies: adopted 2025 ownership-guideline change · Filed 02/04/2026
Position Ownership Requirement Chief Executive Officer 6x Chief Financial Officer 3x Other NEOs 3x In addition to the NEOs, the Viatris share ownership policy covers the most senior employees at Viatris determined by reference to position grade to promote an ownership culture and further align the interests of those leaders with those of shareholders.
Compensation policies: executive ownership multiples · Filed 02/04/2026
Common stock actually owned by the covered employee (including shares of common stock held by the covered employee in the Restoration Plan), as well as restricted shares and unvested RSUs (including corresponding “DEUs”) count toward compliance with these requirements.
Compensation policies: securities counted toward ownership compliance · Filed 02/04/2026
All NEOs meet these share ownership requirements or are expected to meet them by the applicable date.
Compensation policies: qualified statement of ownership compliance · Filed 02/04/2026
The Audit, Compensation, Compliance and Risk Oversight, Executive, Finance, and Governance and Sustainability Committees are composed entirely of independent Directors (as defined in the applicable NASDAQ listing rules and applicable SEC rules).
Board governance: independent committee composition · Filed 02/04/2026
The independent Chair determines the information sent to the Board, the Board’s meeting agendas, and meeting schedules to assure that the Board is properly informed with respect to agenda items in advance and that there is sufficient time for discussion of agenda items at the meetings.
Board governance: independent chair authority · Filed 02/04/2026
Clawback Policy The Board has approved a clawback policy relating to incentive compensation programs.
Compensation governance: approved clawback policy · Filed 02/04/2026
Dimethyl Fumarate The Company launched its generic dimethyl fumarate (“DMF”) product in Europe starting in July 2022 after the European Commission concluded that Biogen was not entitled to regulatory data exclusivity for Tecfidera®.
Intellectual property: Biogen and European dimethyl fumarate launch · Filed 26/02/2026
The Company challenged the European Commission’s revocation decision before the General Court of the European Union (“GCEU”) and, in February 2026, the GCEU denied the Company’s challenge.
Intellectual property: February 2026 denial of authorization-revocation challenge · Filed 26/02/2026
